Revolution Medicines, Inc. ($RVMD)
Filing Information
| Accession Number | 0001610717-26-000137 |
|---|---|
| Form Type | 4 |
| Filing Date | Mar 27, 2026 |
| Document | View SEC Filing |
Transactions
7
Total Shares
112,350
Total Value
$4,837,889.58
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chief Global Commercialization Officer | Common Stock | โ | Mar 25, 2026 | Exercise/Conversion | 37,450 | $33.62 | $1,259,069.00 | 91,850 | Direct | โ | View Details | |
Chief Global Commercialization Officer | Common Stock | โ | Mar 25, 2026 | Sale | 1,800 | $93.22 | $167,801.40 | 90,050 | Direct | โ | View Details | |
Chief Global Commercialization Officer | Common Stock | โ | Mar 25, 2026 | Sale | 3,128 | $94.16 | $294,520.28 | 86,922 | Direct | โ | View Details | |
Chief Global Commercialization Officer | Common Stock | โ | Mar 25, 2026 | Sale | 21,086 | $95.49 | $2,013,415.69 | 65,836 | Direct | โ | View Details | |
Chief Global Commercialization Officer | Common Stock | โ | Mar 25, 2026 | Sale | 11,036 | $96.43 | $1,064,200.38 | 54,800 | Direct | โ | View Details | |
Chief Global Commercialization Officer | Common Stock | โ | Mar 25, 2026 | Sale | 400 | $97.21 | $38,882.84 | 54,400 | Direct | โ | View Details | |
Chief Global Commercialization Officer | Stock Option (Right to Buy) | Derivative | Mar 25, 2026 | Exercise/Conversion | 37,450 | $0.00 | $0.00 | 112,350 | Direct | โ | View Details |